1. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
   Ted W. Johnson et al, 2014, J. Med. Chem. CrossRef
2. Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine
   Jae-Cheol Jo et al, 2017, Ann Hematol CrossRef
3. Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL).
   Therasa Kim et al, 2018, BMC Cancer CrossRef
4. The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma
   Yuko Miyasato et al, 2018, JCEH CrossRef
5. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL
   Yasuo Takashima et al, 2020, Sci Rep CrossRef
6. Analysis of genomic alterations in primary central nervous system lymphoma
   Xin He et al, 2023 CrossRef